Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

Hepatology

Volumn 48, Issue 1, 2008, Pages 204-213

  Ginès, Pere ^a   Wong, Florence ^b   Watson, Hugh ^c   Milutinovic, Slobodan ^d   Del Arbol, Luis Ruiz ^e   Olteanu, Dan ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c SANOFI   (France)

^d Croatian Academy of Medical Sciences   (Croatia)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM; SATAVAPTAN; SODIUM; SPIRONOLACTONE; VASOPRESSIN;

ADULT; AGED; ARTICLE; ASCITES; CIRCULATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERNATREMIA; HYPONATREMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THIRST; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; ASCITES; BLOOD CIRCULATION; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPONATREMIA; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORPHOLINES; RECEPTORS, VASOPRESSIN; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 47149112187     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22293     Document Type: Article

References (21)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
2. Fernández-Llama P, Ginès P, Schrier RW. Pathogenesis of sodium retention in cirrhosis: the arterial vasodilation hypothesis of ascites formation. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Oxford, UK: Blackwell Publishing; 2005:201-214.
3. Angeli P, Gatta A. Medical treatment of ascites in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Oxford, UK: Blackwell Publishing; 2005:227-240.
4. Bataller R, Ginès P, Arroyo V. Practical recommendations for the treatment of ascites and its complications. Drugs 1997;54:571-580.
5. Moore K, Wong F, Ginès P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. HEPATOLOGY 2003;38:258-266.
6. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-2130.
7. Cárdenas A, Ginès P. Management of hyponatremia in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Oxford, UK: Blackwell Publishing; 2005:315-328.
8. Ginès P, Berl T, Bernardi M, Bichet DG, Hamon G, Jiménez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. HEPATOLOGY 1998;28:851-864.
9. Gerbes AL, Gulberg V, Ginès P, Decaux G, Gross P, Gandjini H, et al; VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939.
10. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. HEPATOLOGY 2003;37:182-191.
11. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. New Engl J Med 1996;334:693-699.
12. Ferenci P, Lockwood K, Mullen K, Tarter R, Weisenborn K, Blei AT, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. HEPATOLOGY 2002;35:716-721.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new predictive equation. Ann Intern Med 1999;130:461-470.
14. Angeli P, Wong F, Watson H, Ginès P, for the CAPPS investigators. Hyponatremia in cirrhosis: results of a patient population survey. HEPATOLOGY 2006;44:1535-1542.
15. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993;13:156-162.
16. Angeli P, Pria MD, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of Amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. HEPATOLOGY 1994;19:72-79.
17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec JS, et al. Tolvaptan, a selective V2-vasopressin receptor antagonist, for hyponatremia. N Engl J Med 2006;355;2099-2112.
18. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986;314:1535-1542.
19. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006;119(Suppl 1):S12-S16.
20. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998;63:561-570.
21. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. HEPATOLOGY 2002;36:1197-1205.